文献速递临床免疫分子诊断

Bio-Rad新型HIV筛查试剂Access HIV combo V2的敏感性与特异性评估

Sensitivity and specificity of the new Bio-Rad HIV screening test, Access HIV combo V2.
PubMed 文献 · J Clin Microbiol · 2024-03-27

该研究评估了Access HIV combo V2筛查HIV-1/2的敏感性、特异性及p24抗原检测限。回顾性分析显示对HIV-1慢性感染、HIV-2慢性感染和HIV-1原发感染的敏感性均为100%,前瞻性特异性为99.98%,p24检测限约0.43 IU/mL,表明该试剂适合用于HIV-1/2感染筛查。

要点

  • Access HIV combo V2对HIV-1/2慢性感染及HIV-1原发感染敏感性均为100%。
  • 临床特异性达99.98%(95%CI 99.91-100)。
  • p24抗原检测限约0.43 IU/mL,在11种亚型/CRF中一致。

核心结论

  • Access HIV combo V2具有高敏感性和高特异性,适合作为HIV-1/2感染的筛查试剂。

研究设计与样本

  • 回顾性敏感性分析纳入Pitié-Salpêtrière医院和Bio-Rad实验室的HIV阳性样本,包括HIV-1慢性感染、HIV-1原发感染、HIV-2感染及不同亚型。
  • 前瞻性特异性分析在两家采血机构和Pitié-Salpêtrière医院连续检测6,570例患者样本,与Prism HIV O Plus或Architect HIV Ag/Ab Combo及Procleix Ultrio HIV RNA筛查对比。
  • p24抗原检测限使用重组病毒样颗粒评估,涵盖10种HIV-1 M组亚型/CRF和HIV-1 O组。

主要发现

  • HIV-1慢性感染敏感性为100%(95%CI 99.63-100)。
  • HIV-2慢性感染敏感性为100%(95%CI 98.55-100)。
  • HIV-1原发感染敏感性为100%(95%CI 93.00-100)。
  • 特异性为99.98%(95%CI 99.91-100)。
  • p24抗原检测限约为0.43 IU/mL(四分位距0.38-0.56),在11种分析的亚型/CRF中一致。

关键数值与推荐

  • 敏感性:HIV-1慢性感染100%(99.63-100),HIV-2慢性感染100%(98.55-100),HIV-1原发感染100%(93.00-100)。
  • 特异性:99.98%(99.91-100)。
  • p24检测限:约0.43 IU/mL(IQR 0.38-0.56),在11种亚型/CRF中一致。

临床怎么用

  • Access HIV combo V2可用于HIV-1/2感染的筛查,具有高敏感性和特异性,有助于缩短诊断窗口。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Diagnosing of human immunodeficiency virus (HIV) types 1 and 2 requires a screening with a highly sensitive and specific enzyme immunoassay and a low detection limit for the HIV-1 p24 antigen to minimize the diagnostic window. The objective of the study was to determine the sensitivity, specificity, and p24 limit of detection of the Access HIV combo V2 assay. Retrospective part of sensitivity: 452 HIV-1 positive samples from 403 chronic (9 different HIV-1 group M subtypes, 22 different HIV-1 group M CRFs, and 3 HIV-1 group O), 49 primary HIV-1 infections, 103 HIV-2 positive samples assessed at Pitié-Salpêtrière Hospital, 600 untyped HIV-1, 10 subtype-D, and 159 untyped HIV-2 samples assessed in Bio-Rad Laboratories. Prospective part of clinical specificity: all consecutive samples in two blood donor facilities and Pitié-Salpêtrière (6,570 patients) tested with Access HIV combo V2 and respectively Prism HIV O Plus (Abbott) or Architect HIV Ag/Ab Combo (Abbott) for Ag/Ab screening, and Procleix Ultrio (Gen Probe) for HIV RNA screening. Limit of detection for p24 antigen was assessed on recombinant virus-like particles (10 HIV-1 group M subtypes/CRFs, HIV-1 group O). Sensitivity [95% confidence interval (CI)] of Access HIV combo V2 was 100% (99.63-100) for HIV-1 chronic infection, 100% (98.55-100) for HIV-2 chronic infection, and 100% (93.00-100) for HIV-1 primary infection. Specificity (95% CI) was 99.98 (99.91-100). Limit of detection for p24 antigen was around 0.43 IU/mL [interquartile range (0.38-0.56)], and consistent across the 11 analyzed subtypes/CRFs. Hence, with both high sensitivity and specificity, Access HIV combo V2 is a suitable screening assay for HIV-1/2 infection. IMPORTANCE: Bio-Rad is one of the leading human immunodeficiency virus (HIV) screening test manufacturers. This laboratory released in 2021 their new version of the Access combo HIV test. However, to date, there have been no studies regarding its performance, especially its limit of detection of the diverse p24 antigen. We present the sensitivity (chronic and primary HIV-1 infection and HIV-2 chronic infection), specificity (blood donors and hospitalized patients), and raw data for the p24/seroconversion panels the manufacturer gave to the European agencies.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Guiraud V, Ciczora Y, Cardona M, et al. Sensitivity and specificity of the new Bio-Rad HIV screening test, Access HIV combo V2. J Clin Microbiol. 2024. PMID: 38534108. doi:10.1128/jcm.00095-24

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。